Latest News & Features
Big Pharma
Judge encourages lawyers and public to make their voices heard over transparency concerns | Awkward access to public hearings ‘causing problems’ says Regeneron counsel | Plea for public virtual hearings as judge notes that requests have been ‘coming in by the dozen’ | Panellists discuss at LSPN Europe. 23 November 2023
Big Pharma
The European Patent Office hands a win to BioNTech and Pfizer in coronavirus vaccine dispute | US biotech plans to appeal decision affecting mRNA patent. 23 November 2023
Biotechnology
Recent clashes over patents covering modified guide RNAs have exposed different approaches from the US and Europe—and new complications for the field, says Claire Irvine of HGF. 21 November 2023
Americas
District court’s verdict found NanoString infringed on seven patents related to protein detection tech | Marks the third victory for 10x Genomics in the last six months | NanoString ‘must drop the charade’ says 10x CEO. 21 November 2023
Big Pharma
Big pharma company relies on procedural arguments to fend off a complaint alleging that it engaged in excessive pricing | Feud centres on one of the most successful blockbuster drugs of all time. 16 November 2023
Americas
TwinStrand Biosciences and the University of Washington win patent infringement case related to DNA mutation technology. 16 November 2023
Americas
Securing IP protection in Brazil for the ‘bio-ink’ used to print new human tissue has challenges but composition is key, say Priscila Kashiwabara and Breno Souza of Kasznar Leonardos. 16 November 2023
Americas
New senior counsel joins IP group from previous roles at a Pittsburgh university, robotics company, and founding own law firm | Experience in patent prosecution in tech for life science sectors. 16 November 2023
Biotechnology
Neuroscience-focused biopharma ends litigation with four companies | Companies can introduce generic alternatives in the future. 14 November 2023
Americas
Controversial rule precludes a patent review if there is parallel litigation | Big pharma and tech companies insist the rule is “arbitrary and capricious” |
US agency backs Vidal’s authority, calling a proposed intervention “unnecessary”. 14 November 2023